Pediatric Cardiology

, Volume 37, Issue 5, pp 845–851 | Cite as

Comprehensive Versus Targeted Genetic Testing in Children with Hypertrophic Cardiomyopathy

  • Nathan D. Bales
  • Nicole M. Johnson
  • Daniel P. Judge
  • Anne M. Murphy
Original Article

Abstract

Hypertrophic cardiomyopathy (HCM) is a genetic disease of the sarcomere that can be found in both children and adults and is associated with many causative mutations. In children who are not the index case of HCM in their families, current recommendations call only for targeted genetic testing for familial mutations. However, clinical experience suggests that de novo mutations are possible, as are mutations inherited from apparently an unaffected parent. A chart review was conducted of all patients who received HCM genetic testing at Johns Hopkins from 2004 to 2013. In total, 239 patient charts were analyzed for personal and familial genetic findings. Eighty-one patients with sarcomere gene mutations were identified, of which 66 had a clinical diagnosis of HCM. Importantly, eight patients had >1 pathogenic or likely pathogenic mutation, including six patients who were diagnosed with HCM as children (18 or younger). In this analysis, when a sarcomere mutation is identified in a family, the likelihood of a child with HCM having >1 mutation is 25 % (6/24), compared to 4.8 % (2/42) for adults. The large number of children with multiple mutations suggests that broad panel rather than targeted genetic testing should be considered in HCM presenting during childhood even if the child is not the index case.

Keywords

Hypertrophic cardiomyopathy Genetic counseling Genetic testing 

References

  1. 1.
    Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP (2011) HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 8:1308–1339CrossRefPubMedGoogle Scholar
  2. 2.
    Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, Spirito P, Wright GB, Kanter RJ, Seidman CE, Seidman JG (2005) Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 352:362–372CrossRefPubMedGoogle Scholar
  3. 3.
    Arscott P, Caleshu C, Kotzer K, Kreykes S, Kruisselbrink T, Orland K, Rigelsky C, Smith E, Spoonamore K, Haidle JL, Marvin M, Ackerman MJ, Hadi A, Mani A, Ommen S, Cherny S (2016) A case for inclusion of genetic counselors in cardiac care: a case for genetic counselors. Cardiol Rev 24:49–55CrossRefPubMedGoogle Scholar
  4. 4.
    Bos JM, Towbin JA, Ackerman MJ (2009) Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 54:201–211CrossRefPubMedGoogle Scholar
  5. 5.
    Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 124:e783–e831CrossRefPubMedGoogle Scholar
  6. 6.
    Girolami F, Ho CY, Semsarian C, Baldi M, Will ML, Baldini K, Torricelli F, Yeates L, Cecchi F, Ackerman MJ, Olivotto I (2010) Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol 55:1444–1453CrossRefPubMedGoogle Scholar
  7. 7.
    Hershberger RE, Lindenfeld J, Mestroni L, Seidman CE, Taylor MR, Towbin JA (2009) Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. J Cardiac Fail 15:83–97CrossRefGoogle Scholar
  8. 8.
    Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C (2005) Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet 42:e59CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kaski JP, Syrris P, Esteban MT, Jenkins S, Pantazis A, Deanfield JE, McKenna WJ, Elliott PM (2009) Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2:436–441CrossRefPubMedGoogle Scholar
  10. 10.
    Kelly M, Semsarian C (2009) Multiple mutations in genetic cardiovascular disease: a marker of disease severity? Circ Cardiovasc Genet 2:182–190CrossRefPubMedGoogle Scholar
  11. 11.
    Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287:1308–1320PubMedGoogle Scholar
  12. 12.
    Maron BJ, Maron MS (2013) Hypertrophic cardiomyopathy. Lancet 381:242–255CrossRefPubMedGoogle Scholar
  13. 13.
    Maron BJ, Pelliccia A (2006) The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation 114:1633–1644CrossRefPubMedGoogle Scholar
  14. 14.
    Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO (2009) Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation 119:1085–1092CrossRefPubMedGoogle Scholar
  15. 15.
    Olivotto I, Girolami F, Ackerman MJ, Nistri S, Bos JM, Zachara E, Ommen SR, Theis JL, Vaubel RA, Re F, Armentano C, Poggesi C, Torricelli F, Cecchi F (2008) Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 83:630–638CrossRefPubMedGoogle Scholar
  16. 16.
    Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M (2003) Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107:2227–2232CrossRefPubMedGoogle Scholar
  17. 17.
    Semsarian C, Ingles J, Maron MS, Maron BJ (2015) New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 65:1249–1254CrossRefPubMedGoogle Scholar
  18. 18.
    Tan BY, Judge DP (2012) A clinical approach to a family history of sudden death. Circ Cardiovasc Genet 5:697–705CrossRefPubMedGoogle Scholar
  19. 19.
    Tardiff JC (2005) Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev 10:237–248CrossRefPubMedGoogle Scholar
  20. 20.
    Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP, Seidman JG, Seidman CE (1994) Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 77:701–712CrossRefPubMedGoogle Scholar
  21. 21.
    Tsoutsman T, Kelly M, Ng DC, Tan JE, Tu E, Lam L, Bogoyevitch MA, Seidman CE, Seidman JG, Semsarian C (2008) Severe heart failure and early mortality in a double-mutation mouse model of familial hypertrophic cardiomyopathy. Circulation 117:1820–1831CrossRefPubMedGoogle Scholar
  22. 22.
    Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, Ackerman MJ (2004) Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol 44:1903–1910CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Nathan D. Bales
    • 1
  • Nicole M. Johnson
    • 2
    • 3
  • Daniel P. Judge
    • 3
  • Anne M. Murphy
    • 1
  1. 1.Johns Hopkins Children’s Center M2319Johns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Invitae CorporationSan FranciscoUSA
  3. 3.Division of Cardiology, Department of MedicineJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations